头孢唑林与氯唑西林治疗甲氧西林敏感金黄色葡萄球菌菌血症(CloCeBa):一项前瞻性、开放标签、多中心、非劣效性随机临床试验
CloCeBa研究在法国21家大学与非大学医院纳入315例无血管内植入物或中枢神经系统感染嫌疑的成人MSSA菌血症患者,随机1:1接受头孢唑林(25-50 mg/kg 每8小时静脉)或氯唑西林(25-50 mg/kg 每4-6小时静脉)治疗前7天,后续治疗由研究者选择,总疗程≥14天。主要终点为第3天(心内膜炎第5天)血培养无菌且无复发、生存及第90天临床成功的复合终点,非劣效界值12%。头孢唑林组146例中109例(75%)达标,氯唑西林组146例中108例(74%)达标(差值-1%,95%CI -11至9,p=0.012),达到非劣效。头孢唑林组严重不良事件22/146(15%)少于氯唑西林组40/146(27%)(p=0.010),急性肾损伤氯唑西林组15/128(12%)高于头孢唑林组1/134(1%)(p=0.0002)。
要点
- 头孢唑林组第90天复合终点达标109/146(75%),氯唑西林组108/146(74%),差值-1%(95%CI -11至9),非劣效界值12%,达到非劣效。
- 头孢唑林组严重不良事件22/146(15%),氯唑西林组40/146(27%)(p=0.010)。
- 急性肾损伤氯唑西林组15/128(12%),头孢唑林组1/134(1%)(p=0.0002)。
- 研究纳入成人(≥18岁)MSSA菌血症、无血管内植入物或中枢神经系统感染嫌疑者,头7天头孢唑林25-50 mg/kg 每8小时静脉 vs 氯唑西林25-50 mg/kg 每4-6小时静脉。
适用人群与场景
- 成人(年龄≥18岁)甲氧西林敏感金黄色葡萄球菌(MSSA)菌血症患者。
- 排除有血管内植入物或怀疑中枢神经系统感染者。
处置流程与药物剂量
- 头孢唑林组:头7天头孢唑林25-50 mg/kg 每8小时静脉给药。
- 氯唑西林组:头7天氯唑西林25-50 mg/kg 每4-6小时静脉给药。
- 后续治疗由研究者选择,总疗程≥14天。
研究设计与关键结果
- 研究类型:前瞻性、开放标签、多中心、非劣效性随机临床试验,在法国21家大学与非大学医院开展;2018年9月5日至2023年11月16日纳入315例,随机分配至头孢唑林组(n=158)或氯唑西林组(n=157),排除后每组各146例进入分析。
- 人群平均年龄62.7岁(SD 16.4),男性215例(74%),未收集种族或族裔数据,中位Pitt评分0(IQR 0-0)。
- 主要终点(第3天血培养无菌(心内膜炎第5天)且无复发、生存及第90天临床成功的复合终点):头孢唑林组109/146(75%)vs 氯唑西林组108/146(74%),差值-1%(95%CI -11至9,p=0.012),非劣效界值12%。
- 治疗结束时严重不良事件:头孢唑林组22/146(15%)vs 氯唑西林组40/146(27%)(p=0.010)。
- 急性肾损伤:氯唑西林组15/128(12%)vs 头孢唑林组1/134(1%)(p=0.0002)。
证据类型、等级与局限
- 证据类型:前瞻性、开放标签、多中心、非劣效性随机临床试验。
- 非劣效界值12%。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,头孢唑林可作为氯唑西林治疗MSSA菌血症的替代选择,临床疗效非劣且可能耐受性更好。
指南或共识出处
- CloCeBa试验,注册号ClinicalTrials.gov NCT03248063,由法国卫生部资助。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Although widely used, cefazolin efficacy for the treatment of meticillin-susceptible Staphylococcus aureus (MSSA) bacteraemia has not thus far been investigated in a clinical trial. In this study, we aimed to compare the efficacy and safety of cefazolin with that of cloxacillin in patients with MSSA bacteraemia.
METHODS: We conducted an open-label, non-inferiority, randomised clinical trial in 21 university and non-university hospitals in France in adults (aged ≥18 years) with MSSA bacteraemia, without intravascular implant or suspicion of CNS infection. Participants were randomly assigned (1:1) to receive intravenously cefazolin (25-50 mg/kg every 8 h) or cloxacillin (25-50 mg/kg every 4-6 h) for the first 7 days of therapy using computer-generated blocks of various sizes and stratification on vascular-access associated bacteraemia and centre. Subsequent treatment was left to the choice of the investigator (total duration ≥14 days). The primary endpoint was a composite of sterile blood cultures at day 3 (day 5 for endocarditis) without relapse of bacteraemia, survival, and clinical success at day 90, and was assessed in the intention-to-treat population. A non-inferiority margin of 12% was chosen. This trial is registered on ClinicalTrials.gov (NCT03248063) and is complete.
FINDINGS: Between Sept 5, 2018, and Nov 16, 2023, 315 participants were enrolled and assigned to cefazolin (n=158) or cloxacillin (n=157); 12 participants were excluded from analysis in the cefazolin group, and 11 in the cloxacillin group (final population of 146 in each group). Mean age was 62·7 years (SD 16·4), 215 (74%) participants were male, and race or ethnicity data were not collected. Median Pitt score was 0 (IQR 0-0). The primary endpoint was met in 109 (75%) of 146 participants in the cefazolin group versus 108 (74%) of 146 participants in the cloxacillin group (treatment difference -1%; 95% CI -11 to 9; p=0·012). At the end of study treatment, 22 (15%) of 146 participants assigned to cefazolin and 40 (27%) of 146 participants assigned to cloxacillin had had a serious adverse event (p=0·010). Acute kidney injury occurred more frequently in participants assigned to cloxacillin (15 [12%] of 128) than in those assigned to cefazolin (one [1%] of 134; p=0·0002).
INTERPRETATION: Cefazolin constitutes an alternative to cloxacillin for the treatment of MSSA bacteraemia, offering non-inferior clinical efficacy and potentially enhanced tolerability.
FUNDING: French Ministry of Health.
参考来源
- Burdet C, Saïdani N, Dupieux C, et al. Cloxacillin versus cefazolin for meticillin-susceptible Staphylococcus aureus bacteraemia (CloCeBa): a prospective, open-label, multicentre, non-inferiority, randomised clinical trial. Lancet. 2025. PMID: 41115439. doi:10.1016/S0140-6736(25)01624-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。